# AGENDA: DAY ONE, THURSDAY, SEPTEMBER 30, 2021

8:45AM Welcome Address

SESSION ONE - COVID-19 and SCD - Jo Howard (Invited)

9:00AM COVID-19 in Individuals with Sickle Cell Disease or Sickle Cell Trait

Julie Panepinto, MD

Deputy Director, Division of Blood Diseases and Resources

National Heart, Lung, and Blood Institute

9:30AM COVID Experience Across the Globe

**United Kingdom** 

Subarna Chakravorty, PhD, FRCP, MRCPCH, FRCPath

Consultant Paediatric Haematologist

King's College Hospital

London, UK

9:45AM India

Dipty Jain, MD

Professor and Head, Dept. of Pediatrics

Government Medical College

Nagpur, India

9:55AM Brazil

Clarisse Lobo, PhD

Clinical Research Specialist

**HEMORIO** 

Rio de Janeiro, Brazil

10:10AM Caribbean

Jennifer Knight-Madden, MBBS, PhD

Professor, Pediatric Pulmonology and Clinical Research

Director, Sickle cell Unit of CAIHR University of West Indies Mona

10:25AM BREAK

SESSION TWO – Current and Emerging Therapeutics: Putting out the Fire in Sickle Pathophysiology – Chair: Dr. Kenneth Ataga

10:45AM Reactivation of Fetal Hemoglobin in Adult Erythroid Cells

Bjorg Gudmundsdottir, PhD

Research Fellow, Cellular and Molecular Therapeutics Branch

National Heart, Lung, and Blood Institute

# 11:15AM Activating PK-R, a Therapy for Hemolytic Anemias

Swee Lay Thein, MD Chief, Sickle Cell Branch

National Heart, Lung and Blood Institute

## 11:45PM Improving Red Cell Hydration

Carlo Brugnara, MD

Professor of Pathology, Harvard Medical School

Director, Hematology Laboratory, Boston Children's Hospital

Boston, Massachusetts

## 12:15PM LUNCH

# SESSION THREE - Medical Emergencies in the Older Adult with SCD - Chair: Dr. Enrico Novelli

#### 1:15PM Shortness of Breath - Causes and Management

Parker Ruhl, MD

Associate Research Physician, Physiology Unit National Institute of Allergy and Infectious Diseases

# 1:45PM SCD Nephropathy and Management

Emily Limerick, MD

Staff Clinician, Laboratory of Early Sickle Mortality Prevention

National Heart, Lung, and Blood Institute

# 2:15PM Anticoagulation and Bleeding

Arun Shet, MD

Associate Clinical Investigator, Sickle Cell Branch

National Heart, Lung, and Blood Institute

# 2:45PM Loss of Vision Incl. Retinopathy and Management

Prof. Sobha Sivaprasad

Professor, Institute of Ophthalmology

University College of London

London, UK

# 3:15PM Acute Pain, a Common Presentation for Many Sickle Cell Complications

Laurel Menapace, MD

Staff Clinician, Sickle Cell Branch

National Heart, Lung, and Blood Institute

#### 3:45PM BREAK

# PANEL DISCUSSION – Beyond Hydroxyurea: How and when do we incorporate the new therapies? – Chair: Dr. Marvin Reid

4:00PM Overview of Available Drugs

Charles Quinn, MD

Medical Director, Pediatric Sickle Cell Program Director, Erythrocyte Diagnostic Laboratory

Cincinnati Children's Hospital

4:15PM Panel Contributions from a Global Perspective

David Rees, MA, MBBS, FRCP

Professor of Paediatric Sickle Cell Disease

King's College Hospital

London, UK

Monkia Parshad-Asnani, MBBS, DM, PhD Professor, Family Medicine and Epidemiology

University of West Indies, Jamaica

# AGENDA: DAY TWO, FRIDAY, OCTOBER 1, 2021

9:00AM Welcome Address

# SESSION ONE – Application of New Technologies Part I – Chair: Dr. Marie-Dominique Hardy-Dessources

# 9:15AM Potential Role Of Non-Invasive Point Of Care (POC) And Wearable Optical

**Diagnostics In Sickle Cell Disease** 

Bruce Tromberg, PhD

Director, National Institute of Biomedical Imaging and Bioengineering

National Institutes of Health

# 9:40AM Measuring Sickling of SS and Trait Cells by Slow Deoxygenation

William Eaton, MD, PhD

Chief and Distinguished Investigator, Laboratory of Chemical Physics National Institute of Diabetes and Digestive and Kidney Diseases

National Institutes of Health

# 10:05AM "Oxygen Gradient Ektacytometry (Oxygenscan) and Deformability

Measurements Using the Laser Optical Rotational Red Cell Analyzer"

Philippe Connes, PhD

Professor, Universite Claude Bernard Lyon 1

Head, Vascular biology and Red Blood Cell, LIBM Laboratory

Region de Lyon, France

10:30AM BREAK

# SESSION TWO – Application of New Technology Part II – Chair: Dr. Swee Lay Thein

#### 11:00AM fMRI and Dissection of Pain in SCD

Deepika Darbari, MD Eleni Frangos, PhD Pediatric Hematologist-Oncologist Post-Doctoral Fellow

Children's National Medical Center National Center for Complementary

Washington, DC and Integrative Health

# 11:25AM Al And Machine Learning to Improve Risk Prediction

Vandana Sachdev, MD Xin Tian, PhD

Director, Echocardiography Lab

National Heart, Lung, and Blood

National Heart, Lung, and Blood Institute

Institute

# 11:50AM Mitochondrial DAMP in Sickle Cell Disease

Lax Tumburu, PhD

Staff Scientist, Sickle Cell Branch

National Heart, Lung, and Blood Institute

#### 12:15PM Leukemia and SCD

Courtney Fitzhugh, MD

Tenure Track Investigator, Laboratory of Early Sickle Mortality Prevention

Cellular and Molecular Therapeutics Branch National Heart, Lung, and Blood Institute

# 12:40PM LUNCH

# SESSION THREE – Genetic / Genomic Therapies – Chair: Dr. John Tisdale

# 1:40PM Mechanisms of Disease Reversal After Beta Globin Gene Addition Therapy

Melissa Bonner, PhD VP of Research bluebird bio

Cambridge, Massachusetts

# 2:10PM Update on shmirbcl11a Gene Transfer in Patients with SCD

Erica Esrick, MD

Attending Physician, Dana-Farber/Boston Children's Cancer and Blood Disorders Center

Instructor in Pediatrics, Harvard Medical School

Boston, Massachusetts

# 2:40PM Base Editing Rescues SCD in Human and Mouse Hematopoietic Stem Cell

Models

Greg Newby, PhD Postdoctoral Fellow

Broad Institute of MIT and Harvard

Boston, Massachusetts

#### 3:10PM Prospects for in vivo Gene Editing

Sean Burns, MD

Vice President, Disease Biology

**Intellia Therapeutics** 

Cambridge, Massachusetts

# 3:40PM BREAK

# DEBATE – Should We Aim for Curative Therapies (HSCT And Genetic Therapies) At All Costs? – Chair: Dr. Jennifer Knight-Madden

# 4:00PM Debate

Lakshmanan Krishnamurti, MD

Professor, Pediatrics

**Emory University School of Medicine** 

Atlanta, Georgia

# Debating for Continued Excellent Care in SCD as Curative Therapies are Refined

Jane Little, MD
Professor of Medicine, Division of Hematology and Oncology
Director, UNC Comprehensive Sickle Cell Disease Program
UNC School of Medicine
Chapel Hill, North Carolina

# **Patient Perspective Session**

Successful (TBD)
Unsuccessful - (Jarmanni Cormeaux)
Considering - (Aminu Alibe)

# 5:00PM Thank Yous and Close of Conference

Jennifer Knight-Madden, MBBS, PhD Professor, Pediatric Pulmonology and Clinical Research Director, Sickle cell Unit of CAIHR University of West Indies Mona